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The success rate of drug-administered cardioversion of 
AF depends on many factors such as gender, duration of AF, 
presence of structural heart disease and so forth. According 
to our guidelines for drug-administered cardioversion of AF 
(see www.NVVC.nl), intravenous flecainide, propafenone, 
ibutilide, or vernakalant are recommended (Class 1, level A) 
when pharmacological cardioversion is preferred and there 
is no or minimal structural heart disease. The conversion 
success rate of flecainide is 67–92 % at 6 hours provided 
AF is of < 24 hours onset and its safety is very acceptable. 
On the other hand, spontaneous conversion of recent AF is 
considerable varying from 66 % in cases of < 24 hours from 
onset of symptoms of AF in contrast to 17 % of > 48 hours 
after the onset [6]. Symptomatic < 24 hours AF was shown 
to be a valid predictor for spontaneous cardioversion, fol-
lowed by a normal left ventricular function while the size of 
the left atrium (LA) was of no value [6].
With the purpose to determine the contribution of NT-
proBNP to the selection of patients suitable for a successful 
cardioversion of AF with flecainide, Amin and coworkers 
carried out a prospective study under very specific clinical 
circumstances: symptomatic < 24 hours AF, neither structural 
heart disease, nor left ventricular ejection fraction < 55 %, 
nor severe comorbidity [3]. Already used antiarrhythmic 
or other drugs were maintained during the procedure. As 
expected, a high success rate of conversion (87 %) could be 
achieved without measurable side effects. In the remaining 
13 % of patients without flecainide effect, DC cardioversion 
was successful: all 112 successively included patients in this 
study were discharged in sinus rhythm. Of the baseline char-
acteristics, NT-proBNP was the only independent predictor 
for successful flecainide conversion: at a level < 1550 pg/
ml before flecainide treatment a positive predictive value 
of 94 %, and above this value a negative predictive value 
of 64 % was computed. The left atrial diameter was not an 
Elevated levels of N-terminal pro BNP (NT-proBNP) 
excreted by stretched cardiomyocytes are attributed to 
increased cardiac filling pressures arising, for example, 
in left ventricular relaxation disorders. These conditions 
elicit higher atrial wall stress which in turn can initiate 
mechanisms causing atrial fibrillation (AF). However, the 
presence of AF itself can also produce increased levels of 
NT-proBNP, as was demonstrated by a drop of the peptide 
levels when sinus rhythm resumed after converted AF [1]. 
Not surprisingly, therefore, in the past decade NT-proBNP 
has received much attention as a potential new marker for 
AF detection and management [2].
In 2008, Asselbergs and coworkers reported data of 
the Groningen PREVEND study and showed that newly 
detected AF could be related to elevated NT-proBNP 4 years 
earlier at baseline [3]. A new AF-independent predictor was 
born but its significance was debatable for several reasons 
[4]. Some studies examined the relation of the duration or 
time of onset of AF to NT-proBNP levels, whereas other 
papers demonstrated variable outcomes of the relationship 
between success rates of AF cardioversion and the peptide 
levels (see publications of reference [5]). Conflicting results 
could not promote the role of NT-proBNP as the ideal guide 
for AF detection or management due to the dubious cause-
effect relationship.
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independent predictor for successful flecainide cardiover-
sion. Surprisingly, the predictive value of NT-proBNP was 
completely lost at 14-day follow-up (see table 2, [3]). And, 
also surprising, NT-proBNP levels did not differ in patients 
with sinus rhythm or AF at 14 days of follow-up (see table 
2, [3]).
In our opinion, the message of this study implies no 
immediate consequences for daily practice for several rea-
sons. The outcome of this study in a select group of patients 
has to be confirmed by a new study in the same category 
of patients with comparable methods to comply with the 
learning-testing method. Secondly, if the validity of the 
predictor were to be confirmed, it is doubtful whether one 
would be willing to wait some hours for the laboratory 
results of NT-proBNP tests before starting flecainide con-
version of AF, when faced with a patient with < 24 hours 
of symptomatic AF. As with ‘time is muscle’ in myocardial 
ischaemia, duration of AF strongly determines the success 
of drug-administered cardioversion. Of equal importance: 
is one sure that the AF profile and cardiac condition of the 
patient match that presented by this study? And finally, if 
indeed < 24 hours symptomatic AF is the case, spontaneous 
cardioversion is a serious option: that worldwide experience 
can comfort the patient.
However, we have to acknowledge the study by Amin 
and coworkers because of the observation that different val-
ues of NT-proBNP levels of very recent onset AF could be 
related to the efficacy of flecainide-induced AF cardiover-
sion or not. From a scientific point of view this observa-
tion, made in an almost ideal human AF substrate because of 
absence of confounding factors, counts. Can we explain this 
finding as an epiphenomenon or does a lower NT-proBNP 
baseline level truly reflect less acute atrial remodelling of 
the atria (as well of the ventricles) so that flecainide conver-
sion becomes ‘easier’? Experimental studies can elucidate 
the causal triangle of effects of acute, longer or maintained 
elevated atrial and ventricular atrial stress and stretch, the 
production of NT-proBNP, and the electrophysiological 
substrate for AF cardioversion respectively. Faced with a 
patient with < 24 hours symptomatic AF in the emergency 
room of the hospital, prior to the administration of intrave-
nous flecainide, one can consider reducing the intra-cardiac 
pressure, as reflected by elevated NT-proBNP, with an intra-
venous diuretic. This shot can improve the haemodynamic 
condition for obtaining a successful cardioversion with fle-
cainide. However, this concept also needs to be investigated 
in prospective randomised studies in AF patients with dif-
ferent baseline characteristics.
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